» Articles » PMID: 34470469

The Protective Benefit of Heme Oxygenase-1 Gene-Modified Human Placenta-Derived Mesenchymal Stem Cells in a N-Nitro-L-Arginine Methyl Ester-Induced Preeclampsia-Like Rat Model: Possible Implications for Placental Angiogenesis

Overview
Journal Stem Cells Dev
Date 2021 Sep 2
PMID 34470469
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported that cytoprotective Heme oxygenase-1, HO-1 (HMOX1) gene-modified human placenta-derived mesenchymal stem cell (HO-1-PMSC) improved placental vascularization in vitro. In the current study, we explored the protective benefit of HO-1-PMSC transplantation in a preeclampsia (PE)-like rat model. A model of PE was successfully constructed by intraperitoneal injection of N-nitro-L-arginine methyl ester (L-NAME). Blood pressure and urinary protein levels were measured. Doppler ultrasound was examined to understand uteroplacental perfusion. ELISA was used to examine the serum levels of VEGF, PlGF, sFlt-1, and sEng. The placentas and fetuses were weighed to verify the improvement in pregnancy outcome. Immunohistochemical and H&E staining was used to detect microvessel density (MVD) in placental tissues and kidney pathology, respectively. The distribution of GFP-labeled PMSC in the placenta were observed under fluorescence microscopy. Blood pressure and proteinuria were reduced and kidney damage was improved. PE rat models treated with PMSC and HO-1-PMSC exhibited an increase in the quality of fetuses and placentas, MVD, VEGF, and PlGF expression, but substantially decreased expression of sFlt-1 and sEng. Doppler ultrasound showed that the placental perfusion was improved. Green fluorescent tracing experiments verified that the cells were successfully transplanted into the placenta and distributed in the blood vessels, indicating that the cells might participate in the process of angiogenesis. These results indicate that therapy with HO-1-PMSC could improve placental vascular dysplasia, increase placental perfusion, control PE symptoms, and promote pregnancy outcome by regulating the balance of angiogenic and antiangiogenic factors or directly participating in the repair of placental vessels in a PE-like rat model.

Citing Articles

Transcription coactivator YAP1 promotes CCND1/CDK6 expression, stimulating cell proliferation in cloned cattle placentas.

Wu S, Zhao X, Yang L, Hai C, Wu D, Liu X Zool Res. 2025; 46(1):122-138.

PMID: 39846191 PMC: 11890997. DOI: 10.24272/j.issn.2095-8137.2024.211.


Epicardial transplantation of antioxidant polyurethane scaffold based human amniotic epithelial stem cell patch for myocardial infarction treatment.

Li J, Yao Y, Zhou J, Yang Z, Qiu C, Lu Y Nat Commun. 2024; 15(1):9105.

PMID: 39438477 PMC: 11496666. DOI: 10.1038/s41467-024-53531-8.


Placenta-targeted Treatment Strategies for Preeclampsia and Fetal Growth Restriction: An Opportunity and Major Challenge.

Cui J, Yang Z, Ma R, He W, Tao H, Li Y Stem Cell Rev Rep. 2024; 20(6):1501-1511.

PMID: 38814409 PMC: 11319408. DOI: 10.1007/s12015-024-10739-x.


The Oncogenic Theory of Preeclampsia: Is Amniotic Mesenchymal Stem Cells-Derived PLAC1 Involved?.

Conese M, Napolitano O, Laselva O, Di Gioia S, Nappi L, Trabace L Int J Mol Sci. 2023; 24(4).

PMID: 36835024 PMC: 9962629. DOI: 10.3390/ijms24043612.


The pathological and therapeutic roles of mesenchymal stem cells in preeclampsia.

Jin S, Wu C, Chen M, Sun D, Zhang H Front Med (Lausanne). 2022; 9:923334.

PMID: 35966876 PMC: 9370554. DOI: 10.3389/fmed.2022.923334.